The EU Commission has engaged an independent analysis team to assess the market potential of 13,000 innovations funded under the Horizon program. Among these, the urine diagnostic technology of proteome analysis—used to determine the individual effects of drugs through in-silico modeling—has been recognized as “market-ready” and a “key innovation” with “high market creation potential".

More information can be found here.